**Background**
Skin and soft tissue infections (SSTIs) represent a significant clinical challenge, often caused by a variety of Gram-positive microorganisms. The increasing prevalence of antibiotic-resistant strains, particularly methicillin-resistant Staphylococcus aureus (MRSA) and other coagulase-negative staphylococci, has necessitated the development of novel antibacterial agents with potent activity and low resistance rates. Quinolones have long been utilized for their broad-spectrum activity, but the emergence of mutations in the gyrA and grlA (parC) genes has compromised the efficacy of many traditional fluorinated quinolones. Consequently, there is a critical need for new chemical entities that can overcome these resistance mechanisms. In this context, we will introduce a nonfluorinated quinolone antibacterial – Ozenoxacin.
**Definition**
Ozenoxacin is a nonfluorinated quinolone antibacterial agent that targets quinolone-binding proteins to inhibit bacterial DNA replication. According to the Ozenoxacin description, it is specifically designed to show potent activities against the primary microorganisms isolated from skin and soft tissue infections.
**In Vitro Studies**
The Ozenoxacin biological activity has been extensively evaluated against various clinical isolates. Ozenoxacin In Vitro studies demonstrate potent antibacterial activity against Gram-positive microorganisms, with minimum inhibitory concentrations (MICs) ranging from 0.008 to 4 mg/L. Notably, Ozenoxacin exhibits strong activity against strains of MRSA, MSSA, MSSE, and MRSE, including those possessing 2, 3, or 4 mutations in the gyrA and grlA (parC) genes. Furthermore, research indicates that Ozenoxacin effectively inhibits MSSA and S. agalactiae strains, with resistance rates of >10⁻¹⁰ and 5.3 × 10⁻¹⁰, respectively. The maximum MIC value observed for mutant strains is 8 mg/L. For researchers requiring detailed Ozenoxacin technical information, these results highlight its potential as a powerful tool for combating resistant Gram-positive cocci. In conclusion, Ozenoxacin is a potent nonfluorinated quinolone antibacterial with significant efficacy against quinolone-resistant Gram-positive bacteria.
Keywords
Ozenoxacin, 245765-41-7, T-3912, T3912, T 3912, Bacterial, Antibiotic, Inhibitor, inhibitor, inhibit
References
[1] López Y, et al. In vitro activity of Ozenoxacin against quinolone-susceptible and quinolone-resistant gram-positive bacteria. Antimicrob Agents Chemother. 2013 Dec;57(12):6389-92.
[2] López Y, et al. In vitro selection of mutants resistant to ozenoxacin compared with levofloxacin and ciprofloxacin in Gram-positive cocci. J Antimicrob Chemother. 2015 Jan;70(1):57-61